Anti-Cancer Effects In Human Liver Cancer Cells Produced By Cannabis Agonists
According to preclinical data published online in the journal Toxicology Mechanisms and Methods, the administration of synthetic cannabinoid agonists minimizes cell viability in human hepacarcinoma cells and could be a potential option for treating liver cancer.
The anti-cancer properties of two synthetic cannabinoids, CB65 (CB2 receptor agonist) and ACEA (CB1 receptor agonist) in human hepacarcinoma cells were assessed by investigators from the Tehran University of Medical Sciences, Department of Toxicology and Pharmacology.
It was reported by the authors that the cannabinoid administration minimized malignant cell viability and cell invasion in a dose-dependent manner. “These data suggest ACEA and CB65 as an option for novel treatment of hepatocellular cancer,” they concluded.
Studies in the past have demonstrated that tumor cell growth is inhibited by cannabinoids that also inhibit selectively induced apoptosis by different cell signaling pathways in various types of malignant cells, including gliomas (brain cancers) and lymphomas, prostate, breast, lung, skin, and pancreatic cancer cells.
The study “Evaluation of Anti-invasion Effect of Cannabinoids on Human Hepatocarcinoma Cells,” is available in Toxicology Mechanisms and Methods.